In Vitro Activities of Quinupristin-Dalfopristin and the Streptogramin RPR 106972 against Mycoplasma pneumoniae

ABSTRACT The in vitro activities of quinupristin-dalfopristin and streptogramin RPR 106972 were determined with 44 strains ofMycoplasma pneumoniae and compared to those of macrolides, minocycline, and quinolones. All isolates tested were highly susceptible to macrolides and to quinupristin-dalfopristin (MIC at which 90% of the isolates are inhibited [MIC90], 0.0625 μg/ml), followed by RPR 106972 (MIC90, 0.5 μg/ml), quinolones, and minocycline.

[1]  M. Jacobs,et al.  MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci , 1996, Antimicrobial agents and chemotherapy.

[2]  J. Pechère.  Streptogramins. A unique class of antibiotics. , 1996, Drugs.

[3]  P. Hu,et al.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae , 1995, Antimicrobial agents and chemotherapy.

[4]  A. Barry,et al.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens , 1995, Antimicrobial agents and chemotherapy.

[5]  M. Kaku,et al.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.

[6]  M. Kaku,et al.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.

[7]  R. Wise,et al.  The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. , 1994, The Journal of antimicrobial chemotherapy.

[8]  J. Guerin,et al.  [Treatment of community-acquired pneumonia by pristinamycin (Pyostacine 500). Results of a non comparative open study]. , 1994, Revue de pneumologie clinique.

[9]  K. Waites,et al.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391 , 1991, Antimicrobial Agents and Chemotherapy.

[10]  P. Fernandes,et al.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones , 1988, Antimicrobial Agents and Chemotherapy.

[11]  Y. Osada,et al.  Antimycoplasmal activity of ofloxacin (DL-8280) , 1983, Antimicrobial Agents and Chemotherapy.

[12]  R. Chanock,et al.  Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO. , 1962, Proceedings of the National Academy of Sciences of the United States of America.